Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS–CoV‐2 in an Unvaccinated Cohort

OBJECTIVE: To investigate the impact of biologic disease‐modifying antirheumatic drug (bDMARD) treatment on the prevalence, seroconversion rate, and longevity of the humoral immune response against SARS–CoV‐2 in patients with immune‐mediated inflammatory diseases (IMIDs). METHODS: Anti–SARS–CoV‐2 Ig...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, David, Tascilar, Koray, Kleyer, Arnd, Fagni, Filippo, Krönke, Gerhard, Meder, Christine, Dietrich, Peter, Orlemann, Till, Kliem, Thorsten, Mößner, Johanna, Liphardt, Anna‐Maria, Schönau, Verena, Bohr, Daniela, Schuster, Louis, Hartmann, Fabian, Leppkes, Moritz, Ramming, Andreas, Pachowsky, Milena, Schuch, Florian, Ronneberger, Monika, Kleinert, Stefan, Hueber, Axel J., Manger, Karin, Manger, Bernhard, Atreya, Raja, Berking, Carola, Sticherling, Michael, Neurath, Markus F., Schett, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
COVID‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011429/
https://www.ncbi.nlm.nih.gov/pubmed/34951137
http://dx.doi.org/10.1002/art.42035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011429/
https://www.ncbi.nlm.nih.gov/pubmed/34951137
http://dx.doi.org/10.1002/art.42035

Ejemplares similares